Jason Zemansky
Stock Analyst at B of A Securities
(3.91)
# 640
Out of 5,049 analysts
44
Total ratings
77.42%
Success rate
53.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jason Zemansky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Buy | $142 → $187 | $185.68 | +0.71% | 11 | Oct 27, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $52 → $56 | $60.30 | -7.13% | 5 | Oct 2, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Buy | $9 → $8 | $1.20 | +566.67% | 5 | Aug 25, 2025 | |
| RCKT Rocket Pharmaceuticals | Upgrades: Buy | $4 → $10 | $3.23 | +209.60% | 2 | Aug 20, 2025 | |
| KROS Keros Therapeutics | Downgrades: Neutral | $32 → $18 | $16.17 | +11.32% | 2 | Jun 10, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $29 → $31 | $33.30 | -6.91% | 4 | Apr 1, 2025 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $22 → $17 | $19.56 | -13.09% | 5 | Feb 19, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $36 → $29 | $10.16 | +185.43% | 2 | Nov 22, 2024 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $30 → $31 | $14.69 | +111.03% | 3 | Aug 15, 2024 | |
| ESPR Esperion Therapeutics | Downgrades: Underperform | $2.9 → $2.5 | $2.50 | - | 5 | Jun 20, 2024 |
Insmed
Oct 27, 2025
Maintains: Buy
Price Target: $142 → $187
Current: $185.68
Upside: +0.71%
Cytokinetics
Oct 2, 2025
Maintains: Neutral
Price Target: $52 → $56
Current: $60.30
Upside: -7.13%
Werewolf Therapeutics
Aug 25, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.20
Upside: +566.67%
Rocket Pharmaceuticals
Aug 20, 2025
Upgrades: Buy
Price Target: $4 → $10
Current: $3.23
Upside: +209.60%
Keros Therapeutics
Jun 10, 2025
Downgrades: Neutral
Price Target: $32 → $18
Current: $16.17
Upside: +11.32%
Travere Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $29 → $31
Current: $33.30
Upside: -6.91%
Arcus Biosciences
Feb 19, 2025
Maintains: Neutral
Price Target: $22 → $17
Current: $19.56
Upside: -13.09%
Kura Oncology
Nov 22, 2024
Maintains: Buy
Price Target: $36 → $29
Current: $10.16
Upside: +185.43%
Syndax Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $30 → $31
Current: $14.69
Upside: +111.03%
Esperion Therapeutics
Jun 20, 2024
Downgrades: Underperform
Price Target: $2.9 → $2.5
Current: $2.50
Upside: -